Two scaffolds, one decision point

Choosing between ChondroFiller™ and Arthrosamid® for a painful hip is not a matter of preference — it is a clinical question with a structural answer. The critical filter is lesion morphology: a focal, contained cartilage defect with intact surrounding borders points toward ChondroFiller; a diffuse, arthritic joint where cartilage loss is widespread points toward Arthrosamid. Getting this distinction right matters because the two products work through fundamentally different biology — one is a biodegradable collagen scaffold that supports the body's own repair processes, the other a permanent synthetic hydrogel that cushions and modulates pain. Conflating them produces the wrong result for the patient.

At Lincolnshire Hip, both are delivered as ultrasound-guided outpatient injections in Grantham or Sleaford — so the delivery route is not the differentiator. What separates them is mechanism and indication, both of which are determined by imaging. This article maps the clinical logic behind that selection so that patients arrive at a £250 consultation already oriented, rather than starting from scratch.

How ChondroFiller works in the hip joint

ChondroFiller™ is a CE-marked Class III medical device — acellular Type I collagen, acid-extracted to preserve intact telopeptides and physiological cross-linking capacity. Injected as a liquid under ultrasound guidance in an outpatient setting, it self-gels within minutes inside the cartilage defect, conforming to its shape without any incision or anaesthetic.

The mechanism is acellular matrix-induced chondrogenesis: in plain terms, the scaffold does not contain cells of its own — instead it acts as a chemotactic framework that draws the patient's own progenitor cells in from the surrounding synovium and subchondral bone. Those cells migrate into the collagen matrix, differentiate into chondrocytes, and progressively deposit new cartilage-like tissue as the scaffold itself degrades. The process supports endogenous repair rather than delivering pre-formed tissue.

In terms of hip indication, ChondroFiller is suited to isolated, focal Grade III/IV articular cartilage defects where the surrounding cartilage borders remain healthy and the rest of the joint is structurally sound. Common scenarios include cartilage damage arising from femoroacetabular impingement (FAI), a post-traumatic focal lesion, or contained early deterioration in a younger, active patient whose hip joint space is largely preserved.

On outcomes, published knee series document IKDC score improvements of approximately 30 points over 12 months; in the hip, a modified Harris Hip Score improvement of approximately 30 points has been documented, though dedicated hip RCT data remain limited and these figures should be interpreted accordingly. The archetype patient is broadly: younger, active, focal hip cartilage lesion confirmed on imaging, and not yet presenting with the generalised arthritic change that would shift the clinical decision elsewhere.

How Arthrosamid works in the hip joint

Arthrosamid® works by cushioning rather than repairing. Once administered as a single 6 mL outpatient injection, the 2.5% cross-linked polyacrylamide hydrogel (iPAAG) integrates into the synovial membrane lining of the joint, forming a durable, permanent layer that reduces mechanical friction and modulates pain signals. Unlike ChondroFiller, it contains no biological material, does not degrade over time, and does not promote any form of cartilage regrowth — its role is to absorb load and quiet pain in a joint where cartilage loss is already diffuse.

The product received CE approval in 2021 for symptomatic knee osteoarthritis; its use in the hip joint is currently off-label. That designation reflects the regulatory pathway, not a clinical prohibition: Professor Lee's published work — Maulana, Cole, and Lee, Journal of Arthritis, 2022 — documents outcomes in advanced joint disease, and clinical experience supports meaningful symptom reduction in appropriately selected hip patients.

Pain reduction typically begins around week 4 post-injection, with symptom relief documented out to three years in knee studies. Patients are advised relative joint rest for the first 14 days to allow the hydrogel to integrate; this aftercare requirement is worth factoring into timing.

The Arthrosamid archetype in the hip is almost the clinical mirror-image of the ChondroFiller patient: older, presenting with Kellgren-Lawrence Grade III/IV generalised hip osteoarthritis, having already found viscosupplementation insufficient, and either medically unfit for or not yet ready to proceed to hip replacement. The therapeutic ambition here is clearly defined — sustained pain reduction and preserved function — without any expectation of structural cartilage restoration.

Matching the scaffold to your hip presentation

The primary filter is lesion morphology, determined by MRI. A focal, contained cartilage defect with intact surrounding borders points towards ChondroFiller; diffuse arthritic change without a defined focal lesion points towards Arthrosamid. Kellgren-Lawrence grading on weight-bearing X-ray refines the picture: preserved joint space in early-to-moderate disease aligns with the ChondroFiller pathway, while KL Grade III/IV with global cartilage loss aligns with Arthrosamid.

Age and activity level matter, but they reinforce rather than override morphology. A younger patient with diffuse hip OA does not automatically qualify for ChondroFiller — the collagen scaffold requires a focal defect with healthy borders to function as intended. Equally, an older patient with a well-contained post-traumatic lesion and preserved joint space may remain a candidate for the regenerative pathway regardless of age.

The focal-defect scenario. A patient in their 40s with a contained Grade III cartilage lesion following femoroacetabular impingement, preserved joint space on X-ray, and no prior biologic treatment is a typical ChondroFiller candidate. The imaging locates where the scaffold needs to sit; structural integrity of the surrounding cartilage determines whether host progenitor cells can repopulate it effectively.

The diffuse-OA scenario. A patient in their 60s with KL Grade III/IV generalised hip wear, an inadequate response to viscosupplementation, and either surgical reluctance or significant medical risk factors is a typical Arthrosamid candidate. The clinical ambition here is durable pain reduction rather than tissue restoration.

Treatment history adds further nuance. Failed viscosupplementation in a diffuse-OA hip supports the case for Arthrosamid; a post-FAI hip with no prior biologics, a focal lesion, and preserved borders is an earlier-stage ChondroFiller conversation. Neither scaffold should be selected on symptoms alone — MRI combined with weight-bearing X-ray is required before any pathway decision, as imaging findings are what distinguish one clinical picture from the other.

Evidence base and honest gaps

Neither ChondroFiller™ nor Arthrosamid® has a dedicated hip randomised controlled trial. Both products' primary outcome data and regulatory approvals originate from knee studies, and their application to the hip rests on extrapolation alongside clinical series rather than joint-specific trial evidence.

For ChondroFiller, CE Class III status covers articular cartilage defects across joints without a hip-specific restriction, and Professor Lee's hip practice provides documented clinical precedent. MOCART scaffold-integration scores in the range of 70–87 have been recorded following ChondroFiller use, indicating consistent scaffold engagement — though long-term durability data in the hip's mechanically demanding ball-and-socket environment, which generates different loading patterns from the knee, remains limited.

For Arthrosamid, the three-year knee durability data is the strongest continuity evidence available; whether that timeline holds under hip-specific axial and rotational loading has not been formally tested. Hip use is off-label, as noted earlier — a regulatory distinction that should form part of the informed consent conversation rather than a reason to dismiss the treatment.

The honest clinical position is that both scaffolds carry more uncertainty in the hip than in the knee, but the uncertainty is different in character. For Arthrosamid, the primary question is how durability performs under hip mechanics. For ChondroFiller, it is how reliably the biological repair process proceeds in a higher-stress environment. That distinction matters for setting realistic expectations — and it is why neither pathway can be confirmed on symptoms alone without prior imaging.

Getting assessed at Lincolnshire Hip

Both ChondroFiller and Arthrosamid hip injections are available at Lincolnshire Hip's clinics in Grantham and Sleaford, with no GP referral required to book. A £250 specialist consultation with Professor Paul Lee is the practical entry point — attending with current MRI and weight-bearing X-ray allows imaging findings to determine which scaffold pathway fits, or whether neither is appropriate for the hip presentation in question.

On cost: ChondroFiller is priced from £3,000, which covers ultrasound guidance, the collagen product, intravenous antibiotic cover, and a six-week follow-up review. Arthrosamid pricing is confirmed at consultation. Neither product is currently NHS-funded or covered by standard private medical insurance, so both represent out-of-pocket expenditure that is worth factoring into the decision early. Lincolnshire Hip is part of the MSK Doctors group and accepts patients without referral — and because the scaffold choice rests on imaging morphology rather than symptoms alone, the consultation is where the scans settle the question.